OncoMatch/Clinical Trials/NCT05640999
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Is NCT05640999 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for endometrial cancer.
This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC). Patients may be enrolled in one of two sub-studies * EN10.A/RAINBO BLUE: POLE-mutated EC * EN10.B/TAPER: p53 wildtype / NSMP EC
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Biomarker criteria
Required: POLE mutation
Required: TP53 wild-type
Disease stage
Required: Stage I, II, III
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: surgery
surgery consisting of hysterectomy and bilateral salpingo-oophorectomy
Cannot have received: neoadjuvant chemotherapy
Prior Neoadjuvant chemotherapy for current endometrial cancer diagnosis
Cannot have received: pelvic radiation
Prior pelvic radiation
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Sarasota Memorial Health Care Centre · Sarasota, Florida
- Alaska Womens Cancer Care · Anchorage, Alaska
- University of Arizona Cancer Center · Tucson, Arizona
- Cedars-Sinai Medical Center · Los Angeles, California
- Huntington Memorial Hospital · Pasadena, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05640999 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior neoadjuvant chemotherapy, pelvic radiation disqualifies patients from enrollment.
Does this trial require POLE?
Yes, POLE mutation is a required biomarker for enrollment.
Does this trial require TP53?
Yes, TP53 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage I or II or III is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages